Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Rizatriptan · Maxalt

Small molecule · Agonist of 5-HT1B receptor (HTR1B) and 5-HT1D receptor (HTR1D) · developed by Organon Llc

Approved FDA, Jun 1998
1 Registered trials

What is Rizatriptan?

Rizatriptan is a serotonin 5-HT1B/1D receptor agonist (triptan) that binds to these receptors on intracranial blood vessels and sensory nerves of the trigeminal system.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Maxalt
Drug type
Small molecule
Targets
5-HT1B receptor (HTR1B), 5-HT1D receptor (HTR1D)
Mechanism
Agonist of 5-HT1B receptor (HTR1B) and 5-HT1D receptor (HTR1D)
Therapy area
Neurology
Developer
Organon Llc
In trials of
AXSM
FDA status
Approved as Maxalt (June 29, 1998), NDA020864 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03896009 Phase 3 Migraine Completed AXSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Migraine

Other drugs acting on HTR1B / HTR1D

AXS-07 FDA approved

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.